The Impower010 trial demonstrated that atezolizumab after platinum-based adjuvant chemotherapy improved disease-free survival among patients with stage II to IIIA resected NSCLC, especially in the PD-L1 ≥ 1% [6]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.